A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs ZW 49 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Cancer; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Zymeworks
- 18 Jun 2019 According to the Zymeworks media release, the company has received an offering which is intended to accelerate this trial.
- 28 Jan 2019 Status changed from planning to recruiting.
- 08 Dec 2018 According to a Zymeworks media release, the company has submitted the Investigational New Drug (IND) Application to the US FDA for ZW49 and look forward to start this study.